NCT06254807View on ClinicalTrials.gov

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions
HER2-positive
Interventions
DRUG

CT-0525

Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

Sponsors
All Listed Sponsors
lead

Carisma Therapeutics Inc

INDUSTRY